Literature DB >> 18464017

Preventive effect of oral estetrol in a menopausal hot flush model.

C F Holinka1, M Brincat, H J T Coelingh Bennink.   

Abstract

OBJECTIVE: To evaluate the efficacy of estetrol (E(4)) in alleviating hot flushes in an experimental animal model considered representative for menopausal vasomotor symptoms.
METHODS: Recording of the thermal responses in the tail skin of morphine-dependent ovariectomized rats after morphine withdrawal by administration of naloxone. Six groups of rats were treated orally for 8 days as follows: vehicle (negative) control; E(4): 0.1, 0.3, 1.0 and 3.0 mg/kg/day; and, as active (positive) control, ethinylestradiol 0.3 mg/kg/day. On day 8, tail skin temperature was recorded at baseline and for 60 min at 5-min intervals following naloxone administration. Results In control animals, tail skin temperature increased sharply by about 4.5 degrees C after naloxone treatment and reverted to baseline by 60 min. Estetrol suppressed the tail skin temperature increase in a dose-dependent fashion. The highest dose of E(4) tested (3 mg/kg/day) was equipotent to a 10-fold lower dose of ethinylestradiol. Both fully suppressed tail skin temperature changes.
CONCLUSION: Estetrol is effective in alleviating hot flushes in an experimental animal model considered representative for studying menopausal hot flushes (vasomotor symptoms). In this model, the potency of estetrol is 10-fold lower compared to ethinylestradiol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18464017     DOI: 10.1080/13697130701822807

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  10 in total

1.  A Comprehensive Method To Quantify Adaptations by Male and Female Mice With Hot Flashes Induced by the Neurokinin B Receptor Agonist Senktide.

Authors:  Ashley A Krull; Sarah A Larsen; Donald K Clifton; Genevieve Neal-Perry; Robert A Steiner
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

2.  Effects of Estetrol on Migration and Invasion in T47-D Breast Cancer Cells through the Actin Cytoskeleton.

Authors:  Maria Silvia Giretti; Maria Magdalena Montt Guevara; Elena Cecchi; Paolo Mannella; Giulia Palla; Stefania Spina; Guja Bernacchi; Silvia Di Bello; Andrea Riccardo Genazzani; Alessandro D Genazzani; Tommaso Simoncini
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-26       Impact factor: 5.555

3.  Estradiol shows anti-skin cancer activities through decreasing MDM2 expression.

Authors:  Li Li; Jianguo Feng; Ying Chen; Shun Li; Mengting Ou; Weichao Sun; Liling Tang
Journal:  Oncotarget       Date:  2017-01-31

4.  Buspirone Nanovesicular Nasal System for Non-Hormonal Hot Flushes Treatment.

Authors:  Elka Touitou; Hiba Natsheh; Shaher Duchi
Journal:  Pharmaceutics       Date:  2018-07-03       Impact factor: 6.321

Review 5.  Estetrol and Mammary Gland: Friends or Foes?

Authors:  Anne Gallez; Isabelle Dias Da Silva; Vincent Wuidar; Jean-Michel Foidart; Christel Péqueux
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-08-31       Impact factor: 2.673

Review 6.  Estetrol: A New Choice for Contraception.

Authors:  Franca Fruzzetti; Tiziana Fidecicchi; Maria Magdalena Montt Guevara; Tommaso Simoncini
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

7.  Estetrol Modulates Endothelial Nitric Oxide Synthesis in Human Endothelial Cells.

Authors:  Maria Magdalena Montt-Guevara; Maria Silvia Giretti; Eleonora Russo; Andrea Giannini; Paolo Mannella; Andrea Riccardo Genazzani; Alessandro David Genazzani; Tommaso Simoncini
Journal:  Front Endocrinol (Lausanne)       Date:  2015-07-22       Impact factor: 5.555

8.  The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation.

Authors:  Anne Abot; Coralie Fontaine; Mélissa Buscato; Romain Solinhac; Gilles Flouriot; Aurélie Fabre; Anne Drougard; Shyamala Rajan; Muriel Laine; Alain Milon; Isabelle Muller; Daniel Henrion; Marine Adlanmerini; Marie-Cécile Valéra; Anne Gompel; Céline Gerard; Christel Péqueux; Mélanie Mestdagt; Isabelle Raymond-Letron; Claude Knauf; François Ferriere; Philippe Valet; Pierre Gourdy; Benita S Katzenellenbogen; John A Katzenellenbogen; Françoise Lenfant; Geoffrey L Greene; Jean-Michel Foidart; Jean-François Arnal
Journal:  EMBO Mol Med       Date:  2014-10       Impact factor: 12.137

9.  Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms.

Authors:  Céline Gérard; Mélanie Mestdagt; Ekaterine Tskitishvili; Laudine Communal; Anne Gompel; Elisabete Silva; Jean-François Arnal; Françoise Lenfant; Agnès Noel; Jean-Michel Foidart; Christel Péqueux
Journal:  Oncotarget       Date:  2015-07-10

10.  Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer.

Authors:  Marcus Schmidt; Hans Lenhard; Arnd Hoenig; Yvette Zimmerman; Jan Krijgh; Monique Jansen; Herjan J T Coelingh Bennink
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-26       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.